[terneis]

So good hypothetical here that's definitely not about me at all, let's say I were broke asf and can only afford Ipamorelin on its own. Would pinning ipamorelin by itself with no stack be beneficial and if so how

 

[ltbslayerr33]

prob not

 

[Mandy]

No ipa and other GHRPs are cope and I’d never recommend them

 

[davidmcall1899]

All peptides are cope for bone growth ngl

 

[ltbslayerr33]

All peptides are cope for bone growth ngl

Be a man and take test

 

[shikimori]

So good hypothetical here that's definitely not about me at all, let's say I were broke asf and can only afford Ipamorelin on its own. Would pinning ipamorelin by itself with no stack be beneficial and if so how

Lets see what chatgpt says
"

Here’s the short take: Ipamorelin alone can briefly spike growth hormone (GH), but evidence that it meaningfully improves “growth” (height, muscle, body composition) on its own is weak to none. Details below (educational only, not medical advice).

1) Core findings​

• Acute GH boost: In healthy volunteers, intravenous ipamorelin produced a single GH pulse peaking ~0.67 h after dosing; drug t½ ≈ 2 h; effects waned quickly. [PMID:10496658]
• Selectivity: Unlike older GHRPs, ipamorelin showed little to no ACTH/cortisol rise even at high doses in early studies. [Raun 1998; PMID:9849822]
• Downstream outcomes: No high-quality human trials show sustained IGF-1 elevation or improvements in lean mass/fat with ipamorelin monotherapy. Human ipamorelin trials largely targeted GI motility (ileus) and failed efficacy endpoints (though tolerability was acceptable), not growth/body composition. [Int J Colorectal Dis 2014; FDA summary]
  GRADE:
  • GH pulse (pharmacodynamic effect): Low–Moderate (small Phase I PK/PD in healthy adults). [PMID:10496658]
  • Body composition/“growth” outcomes: Very Low (no robust RCTs; indirect/negative data).
  Bottom line: As a standalone, ipamorelin briefly raises GH but has not shown reliable, clinically meaningful “growth” benefits in humans.

2) Mechanistic deep dive​

• Primary target: Selective agonist of ghrelin receptor (GHSR-1a) on pituitary somatotrophs → Ca²⁺ influx → pulsatile GH release. [Review: Ishida 2020; Sinha 2020]
• Selectivity vs compensatory axes: Compared with GHRP-2/6, ipamorelin minimally affects ACTH/cortisol and prolactin, reducing off-target endocrine noise. [PMID:9849822]
• System level: A single short pulse of GH without sustained IGF-1 rise is unlikely to drive anabolism. Sustained IGF-1 typically requires repeated GHRH drive or longer-acting agonists. (Contrast: oral ibutamoren and tesamorelin increase IGF-1/alter composition in RCTs.)

3) Practical reflection​

• Regulatory/doping: Not FDA-approved for any human indication; appears on WADA S2 (prohibited at all times). Do not use in tested sport.
• Research dosing context (not a recommendation):
  • Phase I PK/PD (IV infusion over 15 min): up to ~0.1 mg/kg produced a single GH pulse; t½ ≈ 2 h; Cl ≈ 0.078 L/h/kg; Vd ≈ 0.22 L/kg. [PMID:10496658]
  • Ileus RCT: 0.03 mg/kg IV twice daily for ≤7 days (ineffective for endpoint).
  • Worked examples at that research dose:
  – 90 kg person → 2.7 mg per dose (IV, BID in trial).
  – 60 kg person → 1.8 mg per dose (IV, BID in trial).
  Note: No validated subcutaneous dosing for “growth/body comp” in peer-reviewed trials.
• Safety signals (class): Ghrelin agonism can increase appetite, cause fluid retention/edema, and touch glucose homeostasis; serious AEs reported with IV use in GI studies. (Oral ghrelin mimetics show ↑appetite, mild edema, ↓insulin sensitivity.)
• Teen growth context: For short stature/GH deficiency, evidence-based care is recombinant GH under pediatric endocrine supervision; peptides like ipamorelin are not indicated.
• €/day: Not reported/standardized (not an approved medicine; “research-use” marketplace varies and is unreliable).

4) Comparison to alternatives​

• Ibutamoren (MK-677; oral GHSR agonist): RCTs in older adults: ↑GH/IGF-1, +fat-free mass, ↑weight; AEs include increased appetite, edema, and reduced insulin sensitivity. Evidence for function is mixed. Not FDA-approved.
• Tesamorelin (GHRH analogue, SC daily): FDA-approved for HIV-associated visceral adiposity; reduces VAT and raises IGF-1 in phase 3 trials. Not indicated for healthy individuals or athletes.
• Recombinant human GH (rx): Strong pediatric evidence for height gain in documented GH deficiency; regulated therapy with defined monitoring.
  Takeaway: If the goal is sustained anabolic signaling (IGF-1), ipamorelin monotherapy is the weakest option among these; alternatives have stronger human data (though each has limitations/risks).

5) Final conclusion​

With current evidence, ipamorelin by itself is not a reliable tool for “boosting growth.” It transiently increases GH but has not shown durable IGF-1 or body-composition benefits in robust human trials. It’s unapproved, banned in sport, and carries class-typical risks. For anyone concerned about height or GH status—especially adolescents—the appropriate path is evaluation by an endocrinologist and, when indicated, approved GH therapy under supervision.

---

(Optional Appendix A) Snapshot evidence table​

• Gobburu 1999 (Phase I, healthy men): IV ipamorelin (4–140 nmol/kg over 15 min). Single GH pulse (Tmax ~0.67 h), t½ ≈ 2 h, dose-proportional PK; no downstream outcomes. [PMID:10496658]
• Raun 1998 (preclinical + early human): High GH selectivity; no cortisol rise even at high doses. [PMID:9849822]
• Int J Colorectal Dis 2014 (Phase II, postoperative ileus): 0.03 mg/kg IV BID up to 7 days; no efficacy benefit, tolerability acceptable. FDA brief notes serious AEs reported with IV use in literature.
• Comparators
  • Ibutamoren RCTs: ↑IGF-1, ↑FFM; AEs: appetite, edema, insulin resistance. [Nass 2008]
  • Tesamorelin Phase 3: ↓VAT, ↑IGF-1; FDA-approved (HIV lipodystrophy).

If you want, tell me your age, goals (height vs muscle vs fat loss), competitive-sport status, and any health conditions/meds—I can tailor a safer, evidence-based path (and flag what’s outright risky or banned)."

 

[Mohammad18347]

So good hypothetical here that's definitely not about me at all, let's say I were broke asf and can only afford Ipamorelin on its own. Would pinning ipamorelin by itself with no stack be beneficial and if so how

No don't spend ur money on that hgh is much better

 

[shikimori]

Lets see what chatgpt says
"

Here’s the short take: Ipamorelin alone can briefly spike growth hormone (GH), but evidence that it meaningfully improves “growth” (height, muscle, body composition) on its own is weak to none. Details below (educational only, not medical advice).

1) Core findings​

• Acute GH boost: In healthy volunteers, intravenous ipamorelin produced a single GH pulse peaking ~0.67 h after dosing; drug t½ ≈ 2 h; effects waned quickly. [PMID:10496658]
• Selectivity: Unlike older GHRPs, ipamorelin showed little to no ACTH/cortisol rise even at high doses in early studies. [Raun 1998; PMID:9849822]
• Downstream outcomes: No high-quality human trials show sustained IGF-1 elevation or improvements in lean mass/fat with ipamorelin monotherapy. Human ipamorelin trials largely targeted GI motility (ileus) and failed efficacy endpoints (though tolerability was acceptable), not growth/body composition. [Int J Colorectal Dis 2014; FDA summary]
  GRADE:
  • GH pulse (pharmacodynamic effect): Low–Moderate (small Phase I PK/PD in healthy adults). [PMID:10496658]
  • Body composition/“growth” outcomes: Very Low (no robust RCTs; indirect/negative data).
  Bottom line: As a standalone, ipamorelin briefly raises GH but has not shown reliable, clinically meaningful “growth” benefits in humans.

2) Mechanistic deep dive​

• Primary target: Selective agonist of ghrelin receptor (GHSR-1a) on pituitary somatotrophs → Ca²⁺ influx → pulsatile GH release. [Review: Ishida 2020; Sinha 2020]
• Selectivity vs compensatory axes: Compared with GHRP-2/6, ipamorelin minimally affects ACTH/cortisol and prolactin, reducing off-target endocrine noise. [PMID:9849822]
• System level: A single short pulse of GH without sustained IGF-1 rise is unlikely to drive anabolism. Sustained IGF-1 typically requires repeated GHRH drive or longer-acting agonists. (Contrast: oral ibutamoren and tesamorelin increase IGF-1/alter composition in RCTs.)

3) Practical reflection​

• Regulatory/doping: Not FDA-approved for any human indication; appears on WADA S2 (prohibited at all times). Do not use in tested sport.
• Research dosing context (not a recommendation):
  • Phase I PK/PD (IV infusion over 15 min): up to ~0.1 mg/kg produced a single GH pulse; t½ ≈ 2 h; Cl ≈ 0.078 L/h/kg; Vd ≈ 0.22 L/kg. [PMID:10496658]
  • Ileus RCT: 0.03 mg/kg IV twice daily for ≤7 days (ineffective for endpoint).
  • Worked examples at that research dose:
  – 90 kg person → 2.7 mg per dose (IV, BID in trial).
  – 60 kg person → 1.8 mg per dose (IV, BID in trial).
  Note: No validated subcutaneous dosing for “growth/body comp” in peer-reviewed trials.
• Safety signals (class): Ghrelin agonism can increase appetite, cause fluid retention/edema, and touch glucose homeostasis; serious AEs reported with IV use in GI studies. (Oral ghrelin mimetics show ↑appetite, mild edema, ↓insulin sensitivity.)
• Teen growth context: For short stature/GH deficiency, evidence-based care is recombinant GH under pediatric endocrine supervision; peptides like ipamorelin are not indicated.
• €/day: Not reported/standardized (not an approved medicine; “research-use” marketplace varies and is unreliable).

4) Comparison to alternatives​

• Ibutamoren (MK-677; oral GHSR agonist): RCTs in older adults: ↑GH/IGF-1, +fat-free mass, ↑weight; AEs include increased appetite, edema, and reduced insulin sensitivity. Evidence for function is mixed. Not FDA-approved.
• Tesamorelin (GHRH analogue, SC daily): FDA-approved for HIV-associated visceral adiposity; reduces VAT and raises IGF-1 in phase 3 trials. Not indicated for healthy individuals or athletes.
• Recombinant human GH (rx): Strong pediatric evidence for height gain in documented GH deficiency; regulated therapy with defined monitoring.
  Takeaway: If the goal is sustained anabolic signaling (IGF-1), ipamorelin monotherapy is the weakest option among these; alternatives have stronger human data (though each has limitations/risks).

5) Final conclusion​

With current evidence, ipamorelin by itself is not a reliable tool for “boosting growth.” It transiently increases GH but has not shown durable IGF-1 or body-composition benefits in robust human trials. It’s unapproved, banned in sport, and carries class-typical risks. For anyone concerned about height or GH status—especially adolescents—the appropriate path is evaluation by an endocrinologist and, when indicated, approved GH therapy under supervision.

---

(Optional Appendix A) Snapshot evidence table​

• Gobburu 1999 (Phase I, healthy men): IV ipamorelin (4–140 nmol/kg over 15 min). Single GH pulse (Tmax ~0.67 h), t½ ≈ 2 h, dose-proportional PK; no downstream outcomes. [PMID:10496658]
• Raun 1998 (preclinical + early human): High GH selectivity; no cortisol rise even at high doses. [PMID:9849822]
• Int J Colorectal Dis 2014 (Phase II, postoperative ileus): 0.03 mg/kg IV BID up to 7 days; no efficacy benefit, tolerability acceptable. FDA brief notes serious AEs reported with IV use in literature.
• Comparators
  • Ibutamoren RCTs: ↑IGF-1, ↑FFM; AEs: appetite, edema, insulin resistance. [Nass 2008]
  • Tesamorelin Phase 3: ↓VAT, ↑IGF-1; FDA-approved (HIV lipodystrophy).

If you want, tell me your age, goals (height vs muscle vs fat loss), competitive-sport status, and any health conditions/meds—I can tailor a safer, evidence-based path (and flag what’s outright risky or banned)."

In conclusion chatgpt says its water by itself lol